{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-22-000084","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.315619+00:00","generated_at":"2026-06-24T08:44:54.769556+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Summit Therapeutics appoints Dr. Maky Zanganeh as Co-CEO & President","bullets":["Dr. Maky Zanganeh appointed Co-CEO & President effective July 25, 2022; formerly COO.","Bob Duggan remains Chairman of the Board and CEO, co-leading with Zanganeh.","Zanganeh previously COO at Pharmacyclics; led key deals including $21B sale to AbbVie and $1B ibrutinib collaboration.","She has been on Summit's board since November 2020 and continues to serve."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-22-000084","json":"https://secwatch.observer/filing/0001599298-22-000084.json","markdown":"https://secwatch.observer/filing/0001599298-22-000084.md","text":"https://secwatch.observer/filing/0001599298-22-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000084/0001599298-22-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000084/smmt-20220725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:44:54.769556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9fa7e215b","claim":"Dr. Maky Zanganeh was appointed as Co-Chief Executive Officer and President at Summit Therapeutics Inc..","evidence_excerpt":"Effective July 25, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000084/0001599298-22-000084-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}